About Us

We operate in partnership with leading research institutions, including Weill Cornell Medical College and the University of Miami’s Bascom Palmer Eye Institute, combining translational research with drug development to create a new standard in vision preservation.

EIR Biopharma is an early-stage biotech company developing targeted therapeutics for eye disease and beyond. Our founding team includes leaders behind Iovance Biotherapeutics, GT Biopharma, and Intercept Pharmaceuticals, with a track record of guiding early-stage innovation through successful IPOs and peak market capitalizations exceeding $15B collectively.

We operate in partnership with leading research institutions to combine translational research with drug development to create a new standard in vision preservation. With exclusive licenses from the University of Miami and Weill Cornell, and research led by NIH-funded scientific founders, we’re bridging advanced neuroscience with real-world patient needs.